Utility of the use of N-acetylcysteine associated with conventional treatment in patients with severe acute alcoholic hepatitis (Maddrey>=32)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-510163-35-00

Acronym

CONACHAA

Enrollment

180

Registered

2025-01-15

Start date

Unknown

Completion date

Unknown

Last updated

2025-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Alcoholic hepatitis

Brief summary

To assess the efficacy of the use of methylprednisolone + NAC, in terms of 1 month mortality, in patients with Severe Acute Alcoholic Hepatitis

Detailed description

To assess mortality at three months and six months, To assess liver complications, infections and renal failure, To assess the tolerance to NAC, To assess the relationship between the Lille index at day 7 and the response to treatment

Interventions

DRUGMETHYLPREDNISOLONE

DRUGACETYLCYSTEINE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
To assess the efficacy of the use of methylprednisolone + NAC, in terms of 1 month mortality, in patients with Severe Acute Alcoholic Hepatitis	—

Secondary

Measure	Time frame
To assess mortality at three months and six months, To assess liver complications, infections and renal failure, To assess the tolerance to NAC, To assess the relationship between the Lille index at day 7 and the response to treatment	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026